| Name | Fusion Antibodies |
|---|---|
| Epic | FAB |
| Isin | GB00BDQZGK16 |
| Industry | Medical Equipment and Services |
| Latest share price | 8.10p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £7.77 | Debt ratio | n/a |
| Shares in issue | 95.95 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -123.22 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -3.9 | 52-week high / low | 2.90p / 10.20p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Fusion Antibodies |
|---|---|
| Address | Springbank Industrial Estate, 1 Springbank Rd, Dunmurry, Belfast, United Kingdom, BT17 0QL |
| Telephone | |
| Website | https://www.fusionantibodies.com/ |
| Director | Position |
|---|---|
| Dr Adrian Kinkaid | CEO |
| Dr Simon Gordon Douglas | Chairman |
| Mr Colin Walsh | Non-Executive Director |
| Mr Matthew Baker | Non-Executive Director |
| Dr Richard John Buick | Chief Scientific Officer |
| Assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Reporting date | 31/03/24 | 31/03/23 | 31/03/22 |
| Intangible asssets and goodwill | n/a | n/a | n/a |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 0.16 | 0.38 | 0.63 |
| Inventory / work in progress | 0.46 | 0.54 | 0.58 |
| Trade and other receivables | 0.6 | 0.95 | 1.65 |
| Cash and equivalents | 1.2 | 0.2 | 2.05 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 2.42 | 2.06 | 4.92 |
| Liabilities £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Short term liabilities | 0.58 | 0.88 | 1.21 |
| Long term liabilities | 0.04 | 0.06 | 0.02 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.63 | 0.94 | 1.23 |
| Net assets £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net assets | 1.79 | 1.12 | 3.68 |
| Equity £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Share capital | 3.81 | 1.04 | 1.04 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -9.77 | -7.56 | -5 |
| Share premium account | 7.74 | 7.65 | 7.65 |
| Total equity | 1.79 | 1.12 | 3.68 |
| Income £ (m) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -2.29 | -2.86 | -1.32 |
| Pre-tax profit | -2.29 | -2.86 | -1.33 |